Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Other Non Operating Income (2017 - 2025)

Puma Biotechnology's Other Non Operating Income history spans 9 years, with the latest figure at $143000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 46.64% year-over-year to $143000.0; the TTM value through Dec 2025 reached $1.0 million, up 19.14%, while the annual FY2025 figure was $1.0 million, 19.14% up from the prior year.
  • Other Non Operating Income reached $143000.0 in Q4 2025 per PBYI's latest filing, up from $115000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $22.5 million in Q4 2021 to a low of -$204000.0 in Q4 2022.
  • Average Other Non Operating Income over 5 years is $1.3 million, with a median of $88500.0 recorded in 2023.
  • The largest YoY upside for Other Non Operating Income was 414.22% in 2023 against a maximum downside of 184.0% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $22.5 million in 2021, then crashed by 100.91% to -$204000.0 in 2022, then soared by 414.22% to $641000.0 in 2023, then crashed by 58.19% to $268000.0 in 2024, then plummeted by 46.64% to $143000.0 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Other Non Operating Income are $143000.0 (Q4 2025), $115000.0 (Q3 2025), and $410000.0 (Q2 2025).